Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma.

[1]  J C Reed,et al.  bcl-2 alters the antigen-driven selection of B cells in mukappa but not in mu-only Xid transgenic mice. , 1996, Journal of immunology.

[2]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[3]  K. Franssila,et al.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. , 1995, Cancer research.

[4]  Z. Oltvai,et al.  Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  John Calvin Reed,et al.  Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function. , 1995, Cell death and differentiation.

[6]  John Calvin Reed,et al.  Structure-Function Analysis of Bcl-2 Protein , 1995, The Journal of Biological Chemistry.

[7]  P. Brousset,et al.  High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. , 1995, Blood.

[8]  John Calvin Reed,et al.  R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl- 2 suppressible mechanism , 1995, The Journal of cell biology.

[9]  J. Martinou,et al.  Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K , 1995, Nature.

[10]  Matthew J. Brauer,et al.  Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak , 1995, Nature.

[11]  G. Evan,et al.  Induction of apoptosis by the Bcl-2 homologue Bak , 1995, Nature.

[12]  R. Weichselbaum,et al.  Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[13]  R. Craig,et al.  The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2 , 1995, The Journal of cell biology.

[14]  J C Reed,et al.  Bcl-2 blocks degranulation but not fas-based cell-mediated cytotoxicity. , 1995, Journal of immunology.

[15]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[16]  E. White,et al.  Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein , 1995, Molecular and cellular biology.

[17]  John Calvin Reed,et al.  Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity , 1995, Cell.

[18]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[19]  T. Noda,et al.  bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. , 1995, Cancer research.

[20]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[21]  R J Miller,et al.  Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. O'Connor,et al.  Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. , 1994, Oncogene.

[23]  John Calvin Reed,et al.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. , 1994, The American journal of pathology.

[24]  S. Mitani,et al.  Rearrangement of bcl‐2 Is Detectable in Hodgkin's Disease by Polymerase Chain Reaction , 1994, Japanese journal of cancer research : Gann.

[25]  John Calvin Reed,et al.  Immunohistochemical analysis of in vivo patterns of Bcl-X expression. , 1994, Cancer research.

[26]  C. Der,et al.  R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells. , 1994, Oncogene.

[27]  T. Jacks,et al.  DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.

[28]  J. M. Boyd,et al.  Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins , 1994, Cell.

[29]  D. Newmeyer,et al.  Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria , 1994, Cell.

[30]  C. Thompson,et al.  bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. , 1994, Development.

[31]  P. Johnson,et al.  Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. , 1994, Oncogene.

[32]  John Calvin Reed,et al.  Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  John Calvin Reed,et al.  Bcl-2 inhibits T-cell-mediated cytolysis of a leukemia cell line. , 1994, Cancer research.

[34]  T. Shenk,et al.  Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Shibata,et al.  BCL2 translocation frequency rises with age in humans. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Wang,et al.  Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death , 1994, Cell.

[37]  M. Rowe,et al.  Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers , 1994, Journal of virology.

[38]  R. Gascoyne,et al.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. , 1994, The American journal of pathology.

[39]  S. Krajewski,et al.  Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. , 1994, Oncogene.

[40]  M. Caligiuri,et al.  The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Borner,et al.  The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis , 1994, The Journal of cell biology.

[42]  M. Karin,et al.  p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.

[43]  C. Thompson,et al.  Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  N. Copeland,et al.  Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme. , 1994, Genes & development.

[45]  J. Rouault,et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells , 1994 .

[46]  G. Dubyak,et al.  Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Krajewski,et al.  Evolutionary conservation of function among mammalian, avian, and viral homologs of the Bcl-2 oncoprotein. , 1994, DNA and cell biology.

[48]  T. McDonnell,et al.  Differential sensitivity of normal and Ha-ras-transformed C3H mouse embryo fibroblasts to tumor necrosis factor: induction of bcl-2, c-myc, and manganese superoxide dismutase in resistant cells. , 1994, Oncogene.

[49]  S. Korsmeyer,et al.  Bcl-2 protein expression during murine development. , 1994, The American journal of pathology.

[50]  M. Clarke,et al.  c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. Taniguchi,et al.  Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 , 1994, Cell.

[52]  Z. Oltvai,et al.  Role of membrane anchor domain of Bcl-2 in suppression of apoptosis caused by E1B-defective adenovirus. , 1994, The Journal of biological chemistry.

[53]  John Calvin Reed,et al.  Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.

[54]  S. Korsmeyer,et al.  Interleukin 7-dependent B lymphocyte precursor cells are ultrasensitive to apoptosis , 1994, The Journal of experimental medicine.

[55]  R. Bristow,et al.  Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. , 1994, Oncogene.

[56]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[57]  John Calvin Reed,et al.  Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. , 1994, Oncogene.

[58]  A. Wyllie,et al.  p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. , 1994, Oncogene.

[59]  F. McCormick,et al.  The Ras-related protein R-ras interacts directly with Raf-1 in a GTP-dependent manner. , 1994, The Biochemical journal.

[60]  Z. Oltvai,et al.  BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax , 1994, Nature.

[61]  T. Hickish,et al.  Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2. , 1994, Cancer research.

[62]  Y. Akao,et al.  Multiple subcellular localization of bcl-2: detection in nuclear outer membrane, endoplasmic reticulum membrane, and mitochondrial membranes. , 1994, Cancer research.

[63]  Masakazu,et al.  The human T-cell leukemia virus type I Tax protein induces apoptosis which is blocked by the Bcl-2 protein , 1994, Journal of virology.

[64]  Stephen S. Gisselbrecht,et al.  Activation of cyclin A-dependent protein kinases during apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  U. Veronesi,et al.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.

[66]  A. Strasser,et al.  The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[67]  John Calvin Reed,et al.  The novel primary response gene MyD118 and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor beta 1-induced apoptosis of myeloid leukemia cells. , 1994, Molecular and cellular biology.

[68]  M. Raff,et al.  Programmed cell death and Bcl‐2 protection in the absence of a nucleus. , 1994, The EMBO journal.

[69]  E. White,et al.  Bcl-2 blocks p53-dependent apoptosis , 1994, Molecular and cellular biology.

[70]  John Calvin Reed,et al.  Cloning and sequencing of a cDNA encoding the rat Bcl-2 protein. , 1994, Gene.

[71]  L. Owen-Schaub,et al.  Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. , 1994, Cancer research.

[72]  E. Wagner,et al.  Down‐regulation of wild‐type p53 activity interferes with apoptosis of IL‐3‐dependent hematopoietic cells following IL‐3 withdrawal. , 1994, The EMBO journal.

[73]  A. Hall,et al.  R-ras interacts with rasGAP, neurofibromin and c-raf but does not regulate cell growth or differentiation. , 1994, Oncogene.

[74]  H. Horvitz,et al.  C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2 , 1994, Cell.

[75]  S. Frisch,et al.  Disruption of epithelial cell-matrix interactions induces apoptosis , 1994, The Journal of cell biology.

[76]  C J Kemp,et al.  The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. , 1994, Cancer research.

[77]  M. Piris,et al.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. , 1994, British Journal of Cancer.

[78]  J. Sprent.  T and B memory cells , 1994, Cell.

[79]  A. Harris,et al.  bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. , 1994, British Journal of Cancer.

[80]  John Calvin Reed,et al.  BCL-2 prevents killing of neuronal cells by glutamate but not by amyloid beta protein. , 1993, Biochemical and biophysical research communications.

[81]  Yi-Song Wang,et al.  Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. , 1993, Oncogene.

[82]  G. Núñez,et al.  Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. , 1993, The American journal of pathology.

[83]  Junying Yuan,et al.  Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 , 1993, Cell.

[84]  Xin Lu,et al.  Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes? , 1993, Cell.

[85]  D. Bredesen,et al.  Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. , 1993, Science.

[86]  J. Bischoff,et al.  Bcl-2 associates with the ras-related protein R-rasp23 , 1993, Nature.

[87]  M. Erdos,et al.  Tyrosine kinase(s) regulate apoptosis and bcl-2 expression in a growth factor-dependent cell line. , 1993, The Journal of biological chemistry.

[88]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[89]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[90]  John Calvin Reed,et al.  Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. , 1993, Cancer research.

[91]  K. Offit,et al.  p53 mutations are associated with histologic transformation of follicular lymphoma. , 1993, Blood.

[92]  D. Longo,et al.  p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.

[93]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[94]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[95]  V. Stewart,et al.  Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. , 1993, Science.

[96]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[97]  John Calvin Reed,et al.  bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .

[98]  Y. Pommier,et al.  bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. , 1993, Cancer research.

[99]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[100]  D. Bredesen,et al.  BCL-2 blocks glutamate toxicity in neural cell lines. , 1993, Brain research. Molecular brain research.

[101]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[102]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[103]  M. Berger,et al.  Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. , 1993, Journal of immunology.

[104]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[105]  J. Hickman,et al.  bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. , 1993, Cancer research.

[106]  S. Nagata,et al.  Effect of bcl-2 on Fas antigen-mediated cell death. , 1993, Journal of immunology.

[107]  N. Harris,et al.  bcl‐2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features , 1993, Cancer.

[108]  D. Rock,et al.  An African swine fever virus gene with similarity to the proto-oncogene bcl-2 and the Epstein-Barr virus gene BHRF1 , 1993, Journal of virology.

[109]  A. Fornace,et al.  Induction of Cellular p53 Activity by DNA-Damaging Agents and Growth Arrest , 1993, Molecular and cellular biology.

[110]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[111]  S. Korsmeyer,et al.  A negative regulatory element in the bcl-2 5'-untranslated region inhibits expression from an upstream promoter , 1993, Molecular and cellular biology.

[112]  John Calvin Reed,et al.  Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. , 1993, The Journal of biological chemistry.

[113]  D. Bredesen,et al.  bcl-2 inhibits death of central neural cells induced by multiple agents. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[114]  G. Dubyak,et al.  Effect of glucocorticosteroid treatment on intracellular calcium homeostasis in mouse lymphoma cells. , 1993, Molecular endocrinology.

[115]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[116]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[117]  A. Davies,et al.  The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis , 1993, Cell.

[118]  S. Korsmeyer,et al.  Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. , 1993, Cancer research.

[119]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[120]  R. Poulsom,et al.  BCL‐2 expression in adult and embryonic non‐haematopoietic tissues , 1993, The Journal of pathology.

[121]  U. Jaeger,et al.  Mechanism of the chromosomal translocation t(14;18) in lymphoma: detection of a 45-Kd breakpoint binding protein. , 1993, Blood.

[122]  L. Ding,et al.  Programmed cell death by bcl‐2‐dependent and independent mechanisms in B lymphoma cells. , 1993, The EMBO journal.

[123]  W. Fiers,et al.  Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. , 1993, Oncogene.

[124]  T. Hennet,et al.  Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. , 1993, Cancer research.

[125]  R. Warnke,et al.  Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. , 1993, The American journal of pathology.

[126]  John Calvin Reed,et al.  Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. , 1993, The Journal of biological chemistry.

[127]  John Calvin Reed,et al.  Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene , 1993, Nature.

[128]  F. Behm,et al.  Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. , 1993, Blood.

[129]  John Calvin Reed,et al.  Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.

[130]  G. Elia,et al.  Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinoma , 1993, International journal of cancer.

[131]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[132]  I. Weissman,et al.  Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. , 1992, Science.

[133]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[134]  H. Zhang,et al.  Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma , 1992, The Lancet.

[135]  M. Dyer,et al.  Ultrastructural localization of bcl-2 protein. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[136]  J C Reed,et al.  Differential effects of Bcl-2 on T and B cells in transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[137]  B. Komm,et al.  Stable expression of the calbindin-D28K complementary DNA interferes with the apoptotic pathway in lymphocytes. , 1992, Molecular endocrinology.

[138]  J. Martinou,et al.  Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. , 1992, Science.

[139]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[140]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[141]  M. Collins,et al.  Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents , 1992, The Journal of experimental medicine.

[142]  John Calvin Reed,et al.  bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. , 1992, Cancer research.

[143]  S. Korsmeyer,et al.  The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[144]  E. Alnemri,et al.  Overexpressed full-length human BCL2 extends the survival of baculovirus-infected Sf9 insect cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[145]  J. Sklar,et al.  Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. , 1992, The American journal of pathology.

[146]  John Calvin Reed,et al.  Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[147]  R. Mertelsmann,et al.  Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. , 1992, Blood.

[148]  I. Weissman,et al.  Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. , 1992, International immunology.

[149]  D. Knowles,et al.  The bcl-2 gene translocation is undetectable in Hodgkin's disease by Southern blot hybridization and polymerase chain reaction. , 1992, The American journal of pathology.

[150]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[151]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[152]  E. White,et al.  The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha , 1992, Molecular and cellular biology.

[153]  M Schena,et al.  Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. , 1992, Blood.

[154]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[155]  Y. Tsujimoto,et al.  Bcl-2 confers growth and survival advantage to interleukin 7-dependent early pre-B cells which become factor independent by a multistep process in culture. , 1992, Oncogene.

[156]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[157]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[158]  M. Pierotti,et al.  bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. , 1992, Blood.

[159]  D. Mason,et al.  Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. , 1992, British Journal of Cancer.

[160]  J. Gribben,et al.  All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.

[161]  D. de Jong,et al.  Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. , 1991, Oncogene.

[162]  John Calvin Reed,et al.  Absence of t(14;18) major and minor breakpoints and of Bcl-2 protein overproduction in Reed-Sternberg cells of Hodgkin's disease. , 1991, The American journal of pathology.

[163]  S. Korsmeyer,et al.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes , 1991, Cell.

[164]  Suzanne Cory,et al.  bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship , 1991, Cell.

[165]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[166]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[167]  I. Maclennan,et al.  Germinal center cells express bcl‐2 protein after activation by signals which prevent their entry into apoptosis , 1991, European journal of immunology.

[168]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[169]  E. Kieff,et al.  Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death , 1991, Cell.

[170]  K. Offit,et al.  Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. , 1991, Blood.

[171]  John Calvin Reed,et al.  Phorbol ester-mediated inhibition of growth and regulation of proto-oncogene expression in the human T cell leukemia line JURKAT. , 1991, Oncogene.

[172]  G. Pinkus,et al.  Absence of bcl-2 major breakpoint region and JH gene rearrangement in lymphocyte predominance Hodgkin's disease. Results of Southern blot analysis and polymerase chain reaction. , 1991, The American journal of pathology.

[173]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[174]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[175]  J. Said,et al.  Polymerase chain reaction for bcl-2 in diagnostic lymph node biopsies. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[176]  M. Kneba,et al.  Sequence analysis of amplified t(14;18) chromosomal breakpoints in B‐cell lymphomas , 1990, The Journal of pathology.

[177]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[178]  D. Mason,et al.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. , 1990, The American journal of pathology.

[179]  M. Stetler-Stevenson,et al.  Involvement of the bcl-2 gene in Hodgkin's disease. , 1990, Journal of the National Cancer Institute.

[180]  S. Korsmeyer,et al.  Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population , 1990, Molecular and cellular biology.

[181]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[182]  P. Nowell,et al.  BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[183]  M. Cleary,et al.  Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. , 1990, The Journal of biological chemistry.

[184]  B. Nathwani,et al.  Detection of specific t(14;18) chromosomal translocations in fixed tissues. , 1990, Human pathology.

[185]  E. White,et al.  Specific disruption of intermediate filaments and the nuclear lamina by the 19-kDa product of the adenovirus E1B oncogene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[186]  S. Kaufmann.  Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. , 1989, Cancer research.

[187]  Y. Tsujimoto.  Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. , 1989, Oncogene.

[188]  C. Croce,et al.  Deregulated BCL2 expression enhances growth of a human B cell line. , 1989, Oncogene.

[189]  S. Korsmeyer,et al.  Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[190]  K. Offit,et al.  18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance , 1989, British journal of haematology.

[191]  M. Oken,et al.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.

[192]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[193]  Y. Tsujimoto.  Overexpression of the human BCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[194]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[195]  D. de Jong,et al.  Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. , 1988, The New England journal of medicine.

[196]  P. Nowell,et al.  Pre-B-cell leukemia with a t(8; 14) and a t(14; 18) translocation is preceded by follicular lymphoma. , 1988, Oncogene.

[197]  Y. Tsujimoto,et al.  The reciprocal partners of both the t(14; 18) and the t(11; 14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. , 1988, Oncogene.

[198]  S. Korsmeyer,et al.  Alternative promoters and exons, somatic mutation and deregulation of the Bcl‐2‐Ig fusion gene in lymphoma. , 1988, The EMBO journal.

[199]  R. Warnke,et al.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. , 1987, The New England journal of medicine.

[200]  E J Freireich,et al.  Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.

[201]  P. Nowell,et al.  Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. , 1987, Science.

[202]  M. Oken,et al.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.

[203]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[204]  D. Gray,et al.  Antigen‐Driven Selection of Virgin and Memory B Cells , 1986, Immunological reviews.

[205]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[206]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[207]  S. Horning,et al.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.

[208]  P. Nowell,et al.  Chromosome translocations and B cell neoplasia. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[209]  J. Rowley,et al.  Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. , 1979, Cancer research.

[210]  Wagenvoort Ca,et al.  Ultrastructural study of contraction of pulmonary vascular smooth muscle cells. , 1976 .

[211]  E. Furth,et al.  The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. , 1995, The American journal of pathology.

[212]  John Calvin Reed,et al.  Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[213]  John Calvin Reed,et al.  Expression of the human BCL‐2 transgene increases the radiation resistance of a hematopoietic progenitor cell line , 1994 .

[214]  John Calvin Reed,et al.  Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[215]  Y. Lévy,et al.  Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. , 1994, The Journal of clinical investigation.

[216]  John Calvin Reed,et al.  Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. , 1994, Antisense research and development.

[217]  D. de Jong,et al.  Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. , 1994, Cancer research.

[218]  J. Minna,et al.  Expression of bcl-2 in small cell lung carcinoma cells. , 1994, Cancer research.

[219]  John Calvin Reed,et al.  Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. , 1993, Antisense research and development.

[220]  F. Cabanillas,et al.  The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[221]  John Calvin Reed,et al.  Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. , 1992, Blood.

[222]  G. Pearson,et al.  Protein kinase activity associated with a cell cycle regulated, membrane-bound Epstein-Barr virus induced early antigen. , 1990, Intervirology.

[223]  P. Nowell,et al.  Regulation of bcl-2 gene expression in lymphoid cell lines containing normal #18 or t(14;18) chromosomes. , 1989, Oncogene research.